Abstract 2107P
Background
Thromboembolic events occur in up to 20% of cancer patients during their course of disease. Cancer associated thrombosis (CAT) is a “signum malum” for cancer itself contributing to morbidity and mortality. Optimal measures to prevent CAT are crucial.
Methods
A post hoc analysis of GMaT & ACT4CAT prospective observational phase IV studies conducted in Greece by Hellenic Society for Medical Oncology (HeSMO), aiming to evaluate efficacy & safety of primary CAT prophylaxis with prophylactic (ProD) or intermediate (InterD; 50%-75% of full treatment dose) doses of Low Molecular Weight Heparins (LMWHs) in ambulatory active cancer patients. Both studies conducted according to Helsinki declaration.
Results
1157 patients from 26 oncology centers were recruited. Age: 64.9±12.3 years, BMI: 26.1±45.1 Kg/m2, 59.9% males. Metastasis in 74.5%, Highly Thrombogenic Agents (HTAs) received 82.3%. Anticoagulation agents were (%): 91.2 tinzaparin, 4.6 fondaparinux, 2.3 bemiparin, 1.2 enoxaparin, 0.8 rivaroxaban or apixaban, for 5.1±3.3 months duration. 62% of patients received InterD (1st, 2nd, 3rd,adjuvant & neoadjuvant: 62.4%, 67.3%, 69.8%, 44.1% &71.4% respectively, p=0.004). InterD preferred in men, in those with metastasis, HTAs treatment and receiving erythropoietin agents (ESA) while ProD in those with history of bleeding, heart or vascular, lung or metabolic disease, immobility, surgery, or radiotherapy. Detailed info in the table. Table: 2107P
InterD (N=701) (N/%) | ProD (N=430) (N/%) | p | OR (95%CI) | |
Males | 416/63.7 | 214/55.4 | 0.008 | 1.4 (1.1-1.8) |
Metastasis | 535/79.0 | 259/67.3 | <.0001 | 1.8 (1.4-2.4) |
HTAs | 597/85.4 | 338/79.2 | 0.007 | 1.5 (1.1-2.1) |
ESA | 133/19.0 | 61/14.2 | 0.038 | 1.4 (1.0-2.0) |
Radiotherapy | 126/18.18 | 106/24.9 | 0.007 | 0.7 (0.5-0.9) |
History of | ||||
Bleeding | 2/0.3 | 6/1.4 | 0.031 | 0.2 (0.0-1.0) |
Heart or vascular disease | 139/28 | 80/35.4 | 0.044 | 0.7 (0.5-0.9) |
Immobility | 43/6.1 | 46/10.7 | 0.006 | 0.6 (0.4-0.8) |
Lung disease | 20/4.0 | 17/7.5 | 0.048 | 0.5 (0.3-0.9) |
Metabolic disease | 96/19.3 | 60/26.6 | 0.028 | 0.7 (0.5-0.9) |
Surgery | 269/38.4 | 250/58.3 | <.0001 | 0.5 (0.4-0.6) |
Bleedings | 11/1.6 | 11/2.6 | 0.242 | 0.6 (0.3-1.4) |
Thrombotic events | 11/1.6 | 20/4.7 | 0.002 | 0.3 (0.2-0.7) |
32 patients (2.8%) had thrombotic events (20 in ProD, 11 in InterD, 1 dose unspecified) with higher risk in ProD (OR: 3.1, 95%CI:1.5-6.5, p=0.0021). 26 minor bleeding events reported (2.3%, no dose related difference, p=0.2424).
Conclusions
Common clinical oncology practice was to administer prophylaxis using in most cases LMWHs and frequently in InterD. Selection of anticoagulation dose was based on demographics, cancer characteristics, treatment type and patient medical history. InterD was found to be more efficacious and without safety concerns.
Clinical trial identification
GMaT: NCT03292107; ACT4CAT: NCT03909399.
Editorial acknowledgement
Dr. Abraham Pouliakis Senior Researcher, 2nd Department of Pathology, National and Kapodistrian University of Athens “ATTIKON”, University Hospital, Athens, Greece.
Legal entity responsible for the study
Hellenic Society of Medical Oncology (HeSMO), Athens, Greece.
Funding
Hellenic Society of Medical Oncology (HeSMO), Athens, Greece.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2028TiP - Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs) expressing DLL3
Presenter: Julien Mazieres
Session: Poster session 06
2029TiP - Phase I study of ABBV-706, an anti-SEZ6 antibody-drug conjugate, alone or in combination in adults with advanced solid tumors
Presenter: Sreenivasa Chandana
Session: Poster session 06
2035P - Routine biomarker monitoring does not replace comprehensive clinical assessment in the detection of immunotherapy induced myocarditis
Presenter: Alexandra Johnson
Session: Poster session 06
2036P - Prevalence and risk evaluation of cardiovascular disease among newly diagnosed prostate cancer population in China
Presenter: Weiyu Zhang
Session: Poster session 06
2037P - Prehabilitation as a strategy to improve postoperative outcomes in frail cancer patients undergoing elective surgery: A systematic review and meta-analysis
Presenter: Muhammed Elfaituri
Session: Poster session 06
2039P - Primary endpoints of confirmatory randomized controlled trials for older patients with cancer: A scoping review
Presenter: Tomonori Mizutani
Session: Poster session 06
2041P - The prevalence of hematologic adverse events (HAEs) and myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) in patients (pts) with advanced high grade ovarian carcinoma (aHGOC) receiving PARP inhibitor (PARPi), with or without a germline BRCA pathogenic variant
Presenter: Carmine Valenza
Session: Poster session 06
2042P - Improving breast cancer outcomes for indigenous women
Presenter: Vita Christie
Session: Poster session 06
2043P - Can Charlson Comorbidity Index (CCI) and Clinical Frailty Scale (CFS) assessments predict survival in octogenarians with colorectal cancer?
Presenter: Neda Nikolic
Session: Poster session 06
2044P - Bloodstream infections (BSI) in cancer patients: Epidemiology, antibiotic therapy and risk factors related to mortality
Presenter: Carlos López Jiménez
Session: Poster session 06